U.S. markets open in 3 hours 43 minutes
  • S&P Futures

    3,814.75
    -24.25 (-0.63%)
     
  • Dow Futures

    31,417.00
    -48.00 (-0.15%)
     
  • Nasdaq Futures

    12,454.50
    -209.25 (-1.65%)
     
  • Russell 2000 Futures

    2,175.50
    -14.20 (-0.65%)
     
  • Crude Oil

    66.14
    +0.05 (+0.08%)
     
  • Gold

    1,690.50
    -8.00 (-0.47%)
     
  • Silver

    25.36
    +0.08 (+0.31%)
     
  • EUR/USD

    1.1884
    -0.0041 (-0.34%)
     
  • 10-Yr Bond

    1.5540
    0.0000 (0.00%)
     
  • Vix

    27.64
    -0.93 (-3.26%)
     
  • GBP/USD

    1.3852
    +0.0024 (+0.18%)
     
  • USD/JPY

    108.4880
    +0.1060 (+0.10%)
     
  • BTC-USD

    50,248.03
    -818.83 (-1.60%)
     
  • CMC Crypto 200

    1,016.95
    +73.78 (+7.82%)
     
  • FTSE 100

    6,621.15
    -9.37 (-0.14%)
     
  • Nikkei 225

    28,743.25
    -121.07 (-0.42%)
     

Do Institutions Own Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Shares?

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·5 min read
  • Oops!
    Something went wrong.
    Please try again later.

Want to participate in a short research study? Help shape the future of investing tools and earn a $40 gift card!

Every investor in Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. Companies that used to be publicly owned tend to have lower insider ownership.

Eloxx Pharmaceuticals is not a large company by global standards. It has a market capitalization of US$121m, which means it wouldn't have the attention of many institutional investors. Our analysis of the ownership of the company, below, shows that institutions are noticeable on the share registry. Let's take a closer look to see what the different types of shareholder can tell us about Eloxx Pharmaceuticals.

View our latest analysis for Eloxx Pharmaceuticals

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Eloxx Pharmaceuticals?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

Eloxx Pharmaceuticals already has institutions on the share registry. Indeed, they own a respectable stake in the company. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Eloxx Pharmaceuticals, (below). Of course, keep in mind that there are other factors to consider, too.

earnings-and-revenue-growth
earnings-and-revenue-growth

We note that hedge funds don't have a meaningful investment in Eloxx Pharmaceuticals. Looking at our data, we can see that the largest shareholder is Pontifax Ltd. with 23% of shares outstanding. Life Sciences Partners BV is the second largest shareholder owning 7.4% of common stock, and Technion Research & Development Foundation Ltd, Endowment Arm holds about 4.9% of the company stock.

We also observed that the top 7 shareholders account for more than half of the share register, with a few smaller shareholders to balance the interests of the larger ones to a certain extent.

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.

Insider Ownership Of Eloxx Pharmaceuticals

The definition of company insiders can be subjective, and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

Our most recent data indicates that insiders own some shares in Eloxx Pharmaceuticals, Inc.. It has a market capitalization of just US$121m, and insiders have US$2.5m worth of shares, in their own names. It is good to see some investment by insiders, but I usually like to see higher insider holdings. It might be worth checking if those insiders have been buying.

General Public Ownership

The general public holds a 28% stake in ELOX. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

Private Equity Ownership

Private equity firms hold a 31% stake in ELOX. This suggests they can be influential in key policy decisions. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.

Public Company Ownership

It appears to us that public companies own 3.2% of Eloxx Pharmaceuticals. This may be a strategic interest and the two companies may have related business interests. It could be that they have de-merged. This holding is probably worth investigating further.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Be aware that Eloxx Pharmaceuticals is showing 3 warning signs in our investment analysis , and 1 of those can't be ignored...

If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.